Toward Personalized Cell Therapies: Autologous Menstrual Blood Cells for Stroke

Department of Neurosurgery and Brain Repair, University of South Florida College of Medicine, 12901 Bruce B. Downs Boulevard, Tampa, FL 33612, USA.
BioMed Research International (Impact Factor: 2.71). 11/2011; 2011(3):194720. DOI: 10.1155/2011/194720
Source: PubMed


Cell therapy has been established as an important field of research with considerable progress in the last years. At the same time, the progressive aging of the population has highlighted the importance of discovering therapeutic alternatives for diseases of high incidence and disability, such as stroke. Menstrual blood is a recently discovered source of stem cells with potential relevance for the treatment of stroke. Migration to the infarct site, modulation of the inflammatory reaction, secretion of neurotrophic factors, and possible differentiation warrant these cells as therapeutic tools. We here propose the use of autologous menstrual blood cells in the restorative treatment of the subacute phase of stroke. We highlight the availability, proliferative capacity, pluripotency, and angiogenic features of these cells and explore their mechanistic pathways of repair. Practical aspects of clinical application of menstrual blood cells for stroke will be discussed, from cell harvesting and cryopreservation to administration to the patient.

Download full-text


Available from: Hiroto Ishikawa
  • Source
    • "Despite intense research to translate these studies from the bench to bedside, critical problems such as low availability, invasive methods for sample collection and low proliferation capacity of wellknown adult stem cell sources, including bone marrow and adipose tissue compared with embryonic stem cells limit the applicability of these cells for clinical use (Henningson et al., 2003; Edwards, 2004). Menstrual blood has now been identified as an easily accessible and recycled stem cell source with some advantages (Czyz et al., 2003; Zhang et al., 2009; Rodrigues et al., 2011a; Lin et al., 2011; Rodrigues et al., 2012a; Allickson and Xiang, 2012): (1) the specimen is obtained by a non-invasive, safe and painless procedure; (2) the use of menstrual blood-derived stem cells (MenSCs) has fewer ethical problems compared with ESCs; (3) the limitations, such as tumor formation, karyotypic abnormalities during cell culture, and immune rejection of consequent allogenic transplantation of MenSCs are restricted; (4) the proliferation rate of MenSCs is much higher than umbilical cord-and bone marrow-derived mesenchymal stem cells (BMSCs); and (5) multipotency of these cells has been established with evidence of their transdifferentiation ability into different lineages, such as osteoblasts (Darzi et al., 2012; Karadas et al., 2012), chondrocytes (Kazemnejad et al., 2012), neurons (Patel et al., 2008; Borlongan et al., 2010) and hepatocytes (Khanjani et al., 2013). These characteristics make menstrual blood as an appropriate stem cell resource for tissue engineering and regeneration medicine. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Menstrual blood is easily accessible, renewable, and inexpensive source of stem cells that have been interested for cell therapy of neurodegenerative diseases. In this study, we showed conversion of menstrual blood stem cells (MenSCs) into clonogenic neurosphere- like cells (NSCs), which can be differentiated into glial-like cells. Moreover, differentiation potential of MenSCs into glial lineage was compared with bone marrow stem cells (BMSCs). Differentiation potential of individual converted NSCs derived from MenSCs or BMSCs into glial-like cells was investigated using immunofluorescence staining and real-time polymerase chain reaction.The fibroblastic morphology of both MenSCs and BMSCs was turned into NSCs shape during first step of differentiation. NSCs derived from both BMSCs and MenSCs expressed higher levels of Olig-2 and Nestin markers compared to undifferentiated cells. The expression levels of myelin basic protein (MBP) mRNA up regulated only in BMSCs-NSCs no in MenSCs-NSCs. However, outgrowth of individual NSCs derived from both MenSCs and BMSCs into glial-like cells led to significant up regulation of glial fibrillary acidic protein,Olig-2 and MBP at mRNA and protein level accompanied with down regulation of Nestin protein.This is the first study demonstrating that MenSCs can be converted to NSCs with differentiation ability into glial-like cells. Accumulative data show different expression pattern of glial markers in differentiated MenSCs compared to BMSCs. The comparable differentiation potential, more accessibility and no invasive technique for sample collection of MenSCs in comparison with BMSCs introduce MenSCs as an apt, consistent and safe alternative to BMSCs for cell therapy of neurodegenerative diseases.
    Full-text · Article · May 2014 · Cell Biology International
    • "There are several advantages in clinical application of MenSCs including: Increased availability in autologous transplantation, lack of ethical conflicts and low immunogenicity due to the lack of MHC class II expression, immunomodulation properties and secretion of neurotrophic factors such as VEGF and angiogenic properties and finally differentiation capacity and express neural markers (MAP 2 and Nestin) in vitro. For these characteristic, MenSCs are suggested as a restorative therapy for post-stroke patients aiming to rehabilitation and functional improvement.[5758] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stroke is an important cause of death in the world and disability world-wide especially in developed countries. Following acute phase of stroke, some procedures and medical treatment such as thrombolytic agents has been recommended; nevertheless many patients have enduring deficits. Thus, there is a realistic need to develop treatment strategies for reducing neurological deficits. However, the stem cell (SC) therapy could arrange an alternative intervention for disease modifying therapy. In this article, we present a brief review of different methods of SC therapy in stroke patients and discuss the results with different cell types and routes of administration.
    No preview · Article · May 2013 · International journal of preventive medicine
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Besides the ovary, the endometrium is one of the most prominent fertility-determining tissues in women. Under the cyclic influence of gonadotropins and steroid hormones, the endometrium is characterized by an enormous regenerative capacity during the female reproductive period. Current evidence suggests that adult stem cells contribute to endometrial regeneration. These cells are characterized by defined stemness-associated marker gene expression patterns, high proliferative potential, long-term culturing properties, and multilineage differentiation potential. Whereas a dysregulated endometrial stem cell function has been linked to the pathogenesis of endometriosis, the therapeutic application of stem cells derived from menstrual blood or transcervical biopsies holds some promise for the therapy of fertility-associated conditions such as Asherman’s syndrome. While the release of endothelial progenitor cells into the circulation is influenced by menstrual-cycle-dependent changes in steroid hormone levels, steroid-receptor negative tissue-resident endometrial stem cells appear to be indirectly stimulated by hormone-receptor positive cells within the endometrial stem cell niche.
    Full-text · Article · Jul 2013 · Journal fur Reproduktionsmedizin und Endokrinologie
Show more